HumanB‐cell and progenitor stages as determined by probability state modeling of multidimensional cytometry data
Open Access
- 8 April 2015
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 88 (4) , 214-226
Abstract
Background Human progenitor and B‐cell development is a highly regulated process characterized by the ordered differential expression of numerous cell‐surface and intracytoplasmic antigens. This study investigates the underlying coordination of these modulations by examining a series of normal bone marrow samples with the method of probability state modeling or PSM. Results The study is divided into two sections. The first section examines B‐cell stages subsequent to CD19 up‐regulation. The second section assesses an earlier differentiation stage before and including CD19 up‐regulation. Post‐CD19 Antigenic Up‐Regulation Statistical analyses of cytometry data derived from sixteen normal bone marrow specimens revealed that B cells have at least three distinct coordinated changes, forming four stages labeled as B1, B2, B3, and B4. At the end of B1; CD34 antigen expression down‐regulates with TdT while CD45, CD81, and CD20 slightly up‐regulate. At the end of B2, CD45 and CD20 up‐regulate. At the end of B3 and beginning of B4; CD10, CD38, and CD81 down‐regulate while CD22 and CD44 up‐regulate. Pre‐CD19 Antigenic Up‐Regulation Statistical analysis of ten normal bone marrows revealed that there are at least two measurable coordinated changes with progenitors, forming three stages labeled as P1, P2, and P3. At the end of P1, CD38 up‐regulates. At the end of P2; CD19, CD10, CD81, CD22, and CD9 up‐regulate while CD44 down‐regulates slightly. Conclusions These objective results yield a clearer immunophenotypic picture of the underlying cellular mechanisms that are operating in these important developmental processes. Also, unambiguously determined stages define what is meant by “normal” B‐cell development and may serve as a preliminary step for the development of highly sensitive minimum residual disease detection systems. A companion article is simultaneously being published in Cytometry Part A that will explain in further detail the theory behind PSM. Three short relevant videos are available in the online supporting information for both of these papers. © 2015 International Clinical Cytometry SocietyKeywords
This publication has 40 references indexed in Scilit:
- The hematopoietic stem cell niche—home for friend and foe?Cytometry Part B: Clinical Cytometry, 2012
- Extracting a cellular hierarchy from high-dimensional cytometry data with SPADENature Biotechnology, 2011
- Ordering human CD34+CD10−CD19+pre/pro-B-cell and CD19−common lymphoid progenitor stages in two pro-B-cell development pathwaysProceedings of the National Academy of Sciences, 2010
- Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histologyCytometry Part B: Clinical Cytometry, 2010
- MIFlowCyt: The minimum information about a flow cytometry experimentCytometry Part A, 2008
- Flowcytometric phenotyping of common variable immunodeficiencyCytometry Part B: Clinical Cytometry, 2008
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- Transcriptional networks in developing and mature B cellsNature Reviews Immunology, 2005
- Leukocyte immunobiology2001
- Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subsetImmunity, 1995